MSF response to license between Pfizer and Medicines Patent Pool for new COVID-19 treatment Paxlovid

As Moderna releases astronomical Q3 sales figures, MSF tells the corporation it’s high time to share the technology with WHO mRNA vaccine tech transfer Hub in South Africa

MSF response to first regulatory approval of first oral antiviral treatment for COVID-19, molnupiravir

MSF responds to BioNTech’s announcement that it will establish production facilities in African countries

License between Merck and Medicines Patent Pool for global production of promising new COVID-19 drug molnupiravir disappoints in its access limitations

MSF responds to another misleading attempt by EU to undermine TRIPS Waiver

MSF warns of deadly TB testing gap following release of WHO Global TB Report 2021

As time runs out to break ‘TRIPS Waiver’ stalemate, protesters at US and EU embassies in South Africa warn “The whole world is watching you.”